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Amyotrophic lateral sclerosis (ALS) is a progressive 
age-dependent neurodegenerative disease characterized 
by degeneration and death of upper (motor cortex) and 
lower (brain stem and spinal cord) motor neurons, 
resulting in muscle atrophy, together with variable 
frontotemporal lobar degeneration (FTLD). ALS may 
be sporadic (sALS) with unknown cause, in up to 90%-
92% of cases, or inherited (fALS), accounting for about 
8-10% of cases, most of them transmitted  as  autosomal  
 
dominant but also recessive and X-linked in some 
families. However, about 13% of sALS cases bear a 
gene mutation linked to fALS. Main pathological 
features in sALS are loss of myelin and axons in the 
pyramidal tracts and anterior spinal roots, chromatolysis 
of motor neurons, axonal spheroids in the anterior horn, 
cystatin C-containing Bunina bodies in motor neurons, 
ubiquitin-immunoreactive TDP-43-positive skein-like 
and spherical inclusions in motor neurons, and TDP-43 
inclusions in oligodendroglial cells. In many cases, the 
frontal cortex shows cytoplasmic TDP-43-immuno-
























2,300  genes  differentially  expressed  in  frontal  cortex  area  8  in  a  single  group  of  typical  sALS  cases without
frontotemporal  dementia  compared with  age‐matched  controls. Main  up‐regulated  clusters  in  the  anterior
horn are related to inflammation and apoptosis; down‐regulated clusters are linked to axoneme structures and
protein  synthesis.  In contrast, up‐regulated gene  clusters  in  frontal cortex area 8  involve neurotransmission,
synaptic  proteins  and  vesicle  trafficking, whereas main  down‐regulated  genes  cluster  into  oligodendrocyte
function  and  myelin‐related  proteins.  RT‐qPCR  validates  the  expression  of  58  of  66  assessed  genes  from
different clusters. The present results: a. reveal regional differences  in de‐regulated gene expression between
the anterior horn of  the spinal cord and  frontal cortex area 8  in the same  individuals suffering  from sALS; b.
validate and extend our knowledge about the complexity of the inflammatory response in the anterior horn of
the  spinal  cord;  and  c.  identify  for  the  first  time  extensive  gene  up‐regulation  of  neurotransmission  and
synaptic‐related  genes,  together  with  significant  down‐regulation  of  oligodendrocyte‐  and  myelin‐related
genes, as  important contributors to the pathogenesis of frontal cortex alterations  in the sALS/frontotemporal
lobar degeneration spectrum complex at stages with no apparent cognitive impairment.   
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reactive intracytoplasmic inclusions in neurons and 
oligodendocytes, and neuropil threads. Neuron loss and 
spongiosis in the upper cortical layers are usually 
restricted to cases with severe cognitive impairment and 
frontotemporal dementia [1, 2]. 
 
Several mechanisms have been proposed as 
contributory factors in the pathogenesis of motor neuron 
damage in sALS including excitoxicity, mitochondrial 
and energy metabolism failure, oxidative stress damage, 
altered glial cells, inflammation, cytoskeletal ab-
normalities, alterations in RNA metabolism, and altered 
TDP-43 metabolism, among others [3-16]. Increased 
understanding on the pathogenesis of sALS has 
emerged from the use of transcriptome analysis of the 
spinal cord and motor cortex [17-26]. Previous 
transcriptomic studies center in the spinal cord and 
motor cortex in separate groups of patients, cover a 
limited number of cases, identify and validate a few 
genes not coincidental among the different studies. 
Selection of the sample may account for these 
differences. Further microarray studies carried out on 
isolated motor neurons of the spinal cord obtained by 
laser micro-dissection in sALS cases have revealed up-
regulation of genes associated with cell signalling and 
cell death and down-regulation of genes linked to 
transcription and composition  of  the cytoskeleton  [27].  
Curiously, similar studies performed on samples from 
individuals bearing mutations linked to ALS show 
different regulated transcripts, thus suggesting gene 
expression variants in the spinal cord in fALS [28, 29].  
 
Importantly, no gene expression analyses are available 
in the frontal cortex area 8 in sALS in spite that frontal 





















and FTLD with TDP inclusions (FTLD-TDP) are within 
the same disease spectrum [1].  
 
The present study analyzes gene expression in the 
anterior horn of the spinal cord and frontal cortex area 8 
in a series of 18 sALS cases and 23 controls. The main 
goals of the present study are to analyze and compare 
gene expression in these two regions, and more 
specifically to identify altered gene expression and 
clusters with specific functions in the anterior horn and 
frontal cortex area 8. Thus, the present study focuses on 
the pathogenesis of motor neuron damage responsible 
of altered motor function, and frontal cortex at 






Cofactors age and gender were not relevant for the 
analysis. 9,563 gene sequences were detected across all 
samples. Heat map indicates differences in transcripts 
expression levels between control and ALS cases in the 
anterior cord of the spinal cord and in frontal cortex 
area 8 (Figure 1). We identified 747 genes differentially 
expressed with p-value lower than or equal to 0.05 in 
the anterior horn of the spinal cord (up: 507 and down: 
240) and 2,300 genes differentially expressed in the 
frontal cortex area 8 (up: 1,409 and down: 891) in sALS 
(Figure 1).  
 
Supplementary Tables 1 and 2 identify all de-regulated 
genes. Post-analysis microarray data of differentially ex-
pressed genes assessed with enrichment analysis against 



























Activation of blood coagulation 
via clotting cascade F3, ANO6 2 2 Inf 0.000574 Up 
Antigen processing and 
presentation of exogenous 
peptide antigen 
CTSS, FCER1G, FCGR1A, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-
DMB, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, 
HLA-DRB5, HLA-F, HLA-G, NCF2, PSMB8, PSMB9, PSMD5, TAP1, 
IFI30 
165 22 6.58 6.84e-11 Up 
Antigen processing and 
presentation of exogenous 
peptide antigen via MHC class I 
CTSS, FCER1G, FCGR1A, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, 
NCF2, PSMB8, PSMB9, PSMD5, TAP1, IFI30 75 14 9.66 2.45e-09 Up 
Antigen processing and 
presentation of exogenous 
peptide antigen via MHC class I, 
TAP-independent 
CTSS, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G 9 6 82.7 1.45e-08 Up 
Antigen processing and 
presentation of exogenous 
peptide antigen via MHC class II 
CTSS, FCER1G, HLA-DMA, HLA-DMB, HLA-DQA1, HLA-DQA2, HLA-
DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, IFI30 92 11 5.66 1.24e-05 Up 
Antigen processing and 
presentation of peptide antigen 
via MHC class I 
CTSS, FCER1G, FCGR1A, HLA-A, HLA-B, HLA-C, HLA-F, HLA-G, 
NCF2, PSMB8, PSMB9, PSMD5, TAP1, IFI30 97 14 7.09 7.58e-08 Up 






















































































































AHR, APOE, FAS, BCL2A1, BCL6, BMP2, BTK, CAMK2D, CASP1, 
CASP4, TNFSF8, CDKN1A, CTSC, DAB2, NQO1, ECT2, EDN1, F3, 
FCER1G, HCK, HGF, HIF1A, HMOX1, ICAM1, IFI16, IL1A, ITGA5, 
JAK3, LMNB1, LYN, MNDA, MYC, NCF2, NOS3, P2RX4, PLAGL1, 
PLAUR, PLSCR1, PRLR, PSMB8, PSMB9, PSMD5, PTPN2, CCL2, 
CCL19, SNAI2, STAT1, TEK, TGFB2, TLR2, TLR3, GPR65, YBX3, 
NOL3, SOCS3, LY86, IKBKE, CHL1, PPP1R15A, RRM2B, SHISA5, 
TNFRSF12A, ACSL5, FNIP2, DNASE2B, ZMAT3, NOA1, FGD3, IL33, 
DEDD2, ANO6 
1745 71 1.89 5.22e-06 Up 
Apoptotic signaling pathway FAS, BCL2A1, BTK, CASP4, CDKN1A, CTSC, ECT2, HGF, HIF1A, 
HMOX1, ICAM1, IFI16, IL1A, NOS3, P2RX4, PLAUR, PTPN2, SNAI2, 
TGFB2, TLR3, YBX3, NOL3, IKBKE, PPP1R15A, RRM2B, SHISA5, 
TNFRSF12A, ACSL5, FNIP2, FGD3, IL33, DEDD2 
596 32 2.43 1.88e-05 Up 
Axonemal dynein complex 
assembly 
DNAH5, DNAI1, TEKT2, ZMYND10, ARMC4, DNAH7, CCDC114, 
CCDC151, DNAAF1, CCDC39 
21 10 175 8.54e-18 Down 
Axoneme DNAH5, DNAH9, SPAG6, DNAI1, DCDC2, HYDIN, CFAP46, ARMC4, 
MNS1, DNAH7, CFAP74, CCDC114, CCDC151, DNAAF1, CFAP54, 
DNAH2, SPAG17, CFAP221, CCDC39, RSPH4A 
89 20 52.5 1.31e-25 Down 
Axoneme assembly DNAH5, DNAI1, TEKT2, ZMYND10, HYDIN, CFAP46, ARMC4, 
DNAH7, CFAP74, RSPH1, CCDC114, CCDC151, DNAAF1, SPAG17, 
CCDC39, RSPH4A 
42 16 128 5.9e-26 Down 
B cell mediated immunity FAS, BCL6, BTK, C1QB, C1QC, C7, FCER1G, HLA-DMA, HLA-DQB1, 
HLA-DRB1, HLA-DRB5, CFI, IL4R, CD226, TLR8 
103 15 7.18 2.28e-08 Up 
Cellular protein modification 
process 
IL12RB1, INS, KCNE1, MAK, CFP, RASA4, TRAK2, MYLK3, NEK5, 
C17orf97, PPIAL4A 
3527 11 0.473 0.00885 Down 
Cellular response to interferon-
gamma 
CAMK2D, EDN1, FCGR1A, GBP1, HCK, HLA-A, HLA-B, HLA-C, HLA-
DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, 
HLA-F, HLA-G, ICAM1, IRF8, OAS2, PTPN2, CCL2, CCL19, STAT1, 
SOCS3, IFI30, TRIM38, TRIM5 
126 27 11.9 1.95e-18 Up 
Clathrin-coated endocytic vesicle 
membrane 
FCGR1A, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-
DRB1, HLA-DRB5 
49 7 7.32 0.000108 Up 
Copper ion import ATP7B, SLC31A1, STEAP4 7 3 30.7 0.000446 Up 
Cytokine production involved in 
immune response 
BCL6, BTK, FCER1G, HLA-A, HMOX1, JAK3, SLC11A1, TEK, TGFB2, 
TLR2, TLR3, TREM1 
69 12 8,81 7,87E-08 Up 
Endolysosome membrane TLR3, TLR7, TLR8 4 3 131 4.51e-05 Up 
Fc receptor mediated stimulatory 
signaling pathway 
FCER1G, FCGR1A, FCGR2A, FGR, HCK, ITPR3, LYN, PLSCR1, 
CD226, MYO1G 
77 10 6.21 1.47e-05 Up 
 
Humoral immune response 
mediated by circulating 
immunoglobulin 
 











Igg binding FCER1G, FCGR1A, FCGR2A, FCGR2B 10 4 28.3 5.42e-05 Up 
Immunoglobulin production FAS, BCL6, CD37, HLA-DQB1, HLA-DRB1, HLA-DRB5, IL4R, 
TNFSF13B, POLM, IL33 
87 10 5.4 4.34e-05 Up 
Inner dynein arm assembly TEKT2, ZMYND10, DNAH7, DNAAF1, CCDC39 10 5 182 1.44e-09 Down 
Integral component of lumenal 
side of endoplasmic reticulum 
membrane 
HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-
DQB2, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G 
28 11 28.8 1.04e-11 Up 
Interferon-alpha production TLR3, NMI, TLR7, TLR8 18 4 11.7 0.000764 Up 
Interferon-beta biosynthetic 
process 
TLR3, NMI, TLR7, TLR8 8 4 41.1 2.12e-05 Up 
Interferon-gamma biosynthetic 
process 
TLR3, EBI3, TLR7, TLR8 16 4 13.7 0.000472 Up 
Interleukin-10 production FCER1G, HLA-DRB1, HLA-DRB5, JAK3, TLR2, PDCD1LG2 42 6 6.87 0.000463 Up 
Intrinsic apoptotic signaling 
pathway
BCL2A1, CASP4, CDKN1A, HIF1A, HMOX1, IFI16, PLAUR, PTPN2, 
SNAI2, YBX3, NOL3, IKBKE, PPP1R15A, RRM2B, SHISA5, FNIP2 
284 16 2.49 0.00143 Up 
Macrophage activation IL4R, SLC11A1, TLR1, SBNO2, CD93, TLR7, TLR8, IL33 48 8 8.29 1.66e-05 Up 
Mast cell cytokine production BCL6, FCER1G, HMOX1 7 3 30.7 0.000446 Up 
MHC class II receptor activity HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1 11 5 35.4 2.73e-06 Up 
MHC protein complex HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DQA1, HLA-
DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, HLA-DRB5, HLA-F, HLA-G 
25 13 48.4 1.34e-15 Up 




















































































































Microtubule bundle formation DNAH5, DNAI1, TEKT2, ZMYND10, HYDIN, CFAP46, ARMC4, 
DNAH7, CFAP74, RSPH1, CCDC114, CCDC151, DNAAF1, SPAG17, 
CCDC39, RSPH4A 
63 16 70.7 1.18e-22 Down 
Monocyte chemotaxis CCR1, LYN, CCL2, CCL19, PLA2G7, ANO6 49 6 5.75 0.00107 Up 
Outer dynein arm assembly DNAH5, DNAI1, ZMYND10, ARMC4, CCDC114, CCDC151, DNAAF1 11 7 325 5.6e-14 Down 
Peptide antigen binding HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-
DRB5, HLA-F, HLA-G, TAP1 
26 10 26.9 1.57e-10 Up 
Platelet-derived growth factor 
receptor binding 
TYMP, ITGA5, ITGB3, LYN 12 4 21.2 0.000123 Up 
Positive regulation of Fc receptor 
mediated stimulatory signaling 
pathway 
LYN, CD226 2 2 Inf 0.000574 Up 
Positive regulation of interleukin-
6 production 
FCER1G, TLR1, TLR2, TLR3, TLR7, IL33 55 6 5.05 0.00197 Up 
Positive regulation of interleukin-
8 production 
TLR2, TLR3, TLR5, TLR7, TLR8 42 5 5.56 0.00318 Up 
Positive regulation of tumor 
necrosis factor production 
FCER1G, CCL2, CCL19, TLR1, TLR2, TLR3 51 6 5.5 0.00133 Up 
Protection from natural killer cell 
mediated cytotoxicity 
HLA-A, HLA-B, TAP1 5 3 61.5 0.000132 Up 
Regulated secretory pathway ANXA3, FCER1G, FGR, HCK, HMOX1, IL4R, LYN, STX11, CD300A, 
RAB11FIP2, RAB11FIP1 
73 11 7.4 1.23e-06 Up 
Regulation of apoptotic process APOE, FAS, BCL2A1, BCL6, BMP2, BTK, CAMK2D, CASP1, CASP4, 
CDKN1A, CTSC, DAB2, NQO1, ECT2, EDN1, F3, FCER1G, HCK, HGF, 
HIF1A, HMOX1, ICAM1, IL1A, ITGA5, JAK3, LYN, MNDA, MYC, 
NCF2, NOS3, PLAUR, PRLR, PSMB8, PSMB9, PSMD5, PTPN2, CCL2, 
CCL19, SNAI2, STAT1, TEK, TGFB2, TLR3, YBX3, NOL3, SOCS3, 
CHL1, RRM2B, TNFRSF12A, ACSL5, ZMAT3, FGD3, DEDD2, ANO6 
1344 54 1.82 0.000117 Up 
Regulation of B cell apoptotic 
process 
BCL6, BTK, LYN 16 3 9.45 0.00608 Up 
Regulation of coagulation APOE, EDN1, F3, FCER1G, LYN, NOS3, PLAU, PLAUR, THBD, HPSE, 
ADAMTS18, ANO6 
85 12 6.87 8.31e-07 Up 
Regulation of cytokine 
biosynthetic process 
CD86, HMOX1, IL1A, TLR1, TLR2, TLR3, NMI, EBI3, TLR7, TLR8 93 10 5.01 7.72e-05 Up 
Regulation of extrinsic apoptotic 
signaling pathway 
FAS, HMOX1, ICAM1, IL1A, NOS3, SNAI2, TGFB2, NOL3, 
TNFRSF12A, ACSL5, DEDD2 
155 11 3.17 0.0013 Up 
Regulation of Fc receptor 
mediated stimulatory signaling 
pathway
LYN, PLSCR1, CD226 5 3 61.5 0.000132 Up 
Regulation of hemostasis APOE, EDN1, F3, FCER1G, LYN, NOS3, PLAU, PLAUR, THBD, HPSE, 
ADAMTS18, ANO6 
81 12 7.27 4.87e-07 Up 
Regulation of leukocyte apoptotic 
process 
BCL6, BTK, FCER1G, HIF1A, JAK3, LYN, CCL19, TGFB2 74 8 5.02 0.000386 Up 
Regulation of lipid kinase 
activity 
FGR, LYN, CCL19, TEK, NRBF2 47 5 4.89 0.0052 Up 
Regulation of mast cell activation FCER1G, FGR, HMOX1, IL4R, LYN, PLSCR1, CD226, CD300A 31 8 14.4 4.96e-07 Up 
Regulation of mast cell 
degranulation 
FCER1G, FGR, HMOX1, IL4R, LYN, CD300A 24 6 13.8 1.71e-05 Up 
Regulation of microtubule 
movement 
DNAH11, ARMC4, DNAAF1, CCDC39 18 4 51.3 3.03e-06 Down 
Regulation of natural killer cell 
mediated immunity 
HLA-A, HLA-B, PVR, TAP1, CD226 27 5 9.36 0.000405 Up 
Regulation of protein metabolic 
process 
FOXJ1, INS, CFP, RASA4, NEK5, DTHD1 2448 6 0.381 0.00803 Down 
Regulation of protein 
modification process 
INS, RASA4 1641 2 0.192 0.00288 Down 
Regulation of T-helper 1 cell 
differentiation 
HLX, IL4R, JAK3, CCL19 9 4 32.9 3.74e-05 Up 
T cell costimulation CD86, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRB1, 
HLA-DRB5, LYN, CCL19, TNFSF13B, PDCD1LG2 
71 11 7.65 9.25e-07 Up 
TAP binding HLA-A, HLA-B, HLA-C, HLA-F, TAP1 7 5 106 1.34e-07 Up 
T-helper 2 cell differentiation BCL6, CD86, HLX, IL4R 14 4 16.4 0.00027 Up 
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Up-regulated genes in ALS anterior horn of the spinal 
cord cluster into inflammatory responses, metal ion regu-
lation and hemostasis; whereas down-regulated genes 
cluster into neuronal axonal cytoskeleton and apoptosis.  
 


















































ed in neurotransmission, ion channels and ion transport, 
synapses, maintenance of axons and dendrites, 
intracellular signaling and synaptic vesicle mechanisms. 
The majority of down-regulated genes were encoded for 
proteins associated with myelin and glial cell regulation 




















































Hierarchical clustering heat map of expression  intensities of mRNA array  transcripts  reflect differential gene expression profiles  in  the
anterior horn of  the spinal cord and  frontal cortex area 8  in ALS compared with controls. Differences between groups are considered
statistically significant at p‐value ≤ 0.05. Abbreviations: ALS: amyotrophic  lateral sclerosis; FC:  frontal cortex area 8; mRNA: messenger
RNA; SP: anterior horn of the spinal cord lumbar level.  























































































































protein coupled receptor signaling 
pathway 
ADCY1, CHRM1, CHRM3, GNAI3, MCHR1, GRM8, HTR1B, HTR1E, 
HTR1F, NPY1R, OPRK1, OPRM1, SSTR2 
64 13 3.79 0.000164 Up 
Astrocyte differentiation ABL1, MAG, NKX2-2, NOTCH1, POU3F2, S100B, TAL1, CNTN2, SOX8 53 9 5.12 0.000184 Down 
Axolemma KCNC1, KCNC2, KCNH1, ROBO2, SLC1A2 14 5 8.26 0.00124 Up 
Axon 
DAGLA, CAMK2D, CCK, CHRM1, CHRM3, AP1S1, CTNNA2, DLG4, 
DRD1, EPHA4, PTK2B, FGF13, GAP43, GARS, GRIA1, GRIK5, 
GRIN2A, HTR2A, KCNB1, KCNC1, KCNC2, KCNH1, KCNK2, 
KCNMA1, KCNQ2, KCNQ3, MYH10, NPY1R, NRCAM, NRGN, OPRK1, 
PAK1, PFN2, MAP2K1, PTPRN2, ROBO2, SCN1A, SCN1B, SCN2A, 
SCN8A, CCL2, SLC1A2, SNCA, STXBP1, SYN1, KCNAB1, FZD3, 
GLRA3, PRSS12, CNTNAP1, KCNAB2, NRP1, CDK5R1, BSN, SYT7, 
SYNGR1, DGKI, NRXN1, HOMER1, KATNB1, SEMA3A, OLFM1, 
SLC9A6, CPLX1, AAK1, ADGRL1, TPX2, UNC13A, MYCBP2, NCS1, 
PACSIN1, STMN3, SEPT11, SLC17A7, TBC1D24, NDEL1, LMTK3, 
MTPN, CNTN4, LRRTM1, HCN1 
358 81 4.6 1.68e-24 Up 
Axon extension BMPR2, NRCAM, PPP3CB, SLIT1, CDKL5, NRP1, CDK5R1, LHX2, 
SEMA3A, OLFM1, SLC9A6, BCL11A, ISLR2, NDEL1 
91 14 2.7 0.00176 Up 
Axon hillock CCK, TPX2, NDEL1 7 3 11.1 0.00729 Up 
Cadherin binding CDH13, CTNNA2, TRPC4, CDK5R1, AKAP5, MMP24, PTPRT 29 7 4.81 0.00167 Up 
Calcineurin complex ITPR1, PPP3CA, PPP3CB, PPP3R1 4 4 Inf 1.59e-05 Up 
Calcium channel regulator activity CACNB2, FKBP1B, ITPR1, PRKCB, STX1A, NRXN1, TSPAN13, 
HPCAL4, CACNA2D3 
36 9 5.05 0.000281 Up 
Calcium ion-dependent exocytosis 
of neurotransmitter 
CACNA1A, SYT1, SYT5, DOC2A, SYT7, RIMS2, RAB3GAP1, RIMS1, 
SYT13, SYT12 
28 10 8.25 4.76e-06 Up 
Calmodulin binding ADCY1, ADD2, ATP2B1, ATP2B2, CACNA1C, CAMK4, CAMK2A, 
CAMK2B, CAMK2D, GAP43, ITPKA, KCNH1, KCNN1, KCNQ3, MAP2, 
MYH10, MYO5A, NOS2, NRGN, PDE1B, PPP3CA, PPP3CB, PPP3R1, 
RGS4, RIT2, RYR2, SLC8A2, SLC8A1, AKAP5, CAMKK2, ARPP21, 
PLCB1, KCNH5, CAMK1D, CAMK1G, CAMKV, CAMKK1, PNCK, 
CFAP221, RIIAD1 
176 40 4.57 5.38e-13 Up 
Calmodulin-dependent protein 
kinase activity 
CAMK4, CAMK2A, CAMK2B, CAMK2D, PTK2B, ITPKA, CAMKK2, 
CAMK1D, CAMK1G, CAMKK1, PNCK 
32 11 7.95 2.02e-06 Up 
Camp binding PDE2A, PDE4A, PRKAR1B, PRKAR2B, RAPGEF2, RAPGEF4, HCN1 24 7 6.23 0.000487 Up 
Central nervous system neuron 
axonogenesis 
EPHA4, SCN1B, NR2E1, MYCBP2, PRDM8, ARHGEF28, NDEL1 29 7 4.71 0.00187 Up 
Chloride channel activity CLIC2, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRB2, 
GABRB3, GABRD, GABRG3, GLRB, SLC26A4, GLRA3, SLC17A7, 
SLC26A8, ANO5 
78 16 3.93 2.05e-05 Up 
Clathrin binding SYT1, SYT5, DOC2A, SYT7, SNAP91, HMP19, SYTL2, CEMIP, SYT13, 
SMAP1, SYT16, SYT12 
56 12 4.14 0.000141 Up 
Compact myelin MAG, SIRT2, JAM3 12 3 8.38 0.00957 Down 
Cyclin-dependent protein 
serine/threonine kinase activity 
CDK14, CDKL5, CDKL1, CDK5R1, CDKL2, CDK20 29 6 3.94 0.008 Up 
Cytoskeleton of presynaptic active 
zone 
BSN, PCLO 2 2 Inf 0.004 Up 
Dendrite BMPR2, CACNA1A, CACNA1B, CACNA1C, CCK, CHRM1, CHRM3, 
CRMP1, DLG3, DLG4, DRD1, EPHA4, EPHA7, PTK2B, FGF13, 
GABRA5, GRIA1, GRIA2, GRIA3, GRIK5, GRIN2A, GRM1, GRM5, 
HTR2A, ITPKA, KCNB1, KCNC1, KCNC2, KCND3, KCNH1, KCNJ4, 
KCNQ3, MAP2, MYH10, NELL2, NRGN, OPRK1, PAK1, PRKAR2B, 
PRKCG, MAP2K1, RARA, RGS7, SCN8A, CCL2, SLC8A1, CDKL5, 
SYN1, KCNAB1, FZD3, PRSS12, CDK5R1, BSN, NEURL1, DGKI, 
HOMER1, CABP1, AKAP5, ARHGAP32, FRMPD4, SEMA3A, BAIAP2, 
SLC9A6, ARFGEF2, CHL1, PLK2, CPLX1, LZTS1, CPEB3, NCS1, 
NSMF, SHANK1, IFT57, SEPT11, ANKS1B, SLC4A10, TENM2, 
DLGAP3, JPH4, PPP1R9B, SHANK3, LMTK3, GRIN3A, SNAP47, 
CNIH2, HCN1 
406 86 4.24 7.25e-24 Up 
 





















































































































Dendrite development ADGRB3, CACNA1A, CAMK2B, CTNNA2, DLG4, EPHA4, HPRT1, 
ITPKA, MAP2, MEF2C, PAK1, PAK3, PPP3CA, CDKL5, NR2E1, NRP1, 
CDK5R1, NEURL1, AKAP5, RAPGEF2, KIAA0319, SEMA3A, BAIAP2, 
SLC9A6, PLK2, CIT, LZTS1, CPEB3, NEDD4L, MAPK8IP2, RBFOX2, 
NGEF, NSMF, SLITRK5, PACSIN1, SHANK1, DCDC2, BCL11A, 
FEZF2, CAMK1D, SHANK3, GRIN3A, FMN1 
178 43 4.85 1.44e-14 Up 
Dendrite extension PARK2, SYT1, RIMS2, SLC9A6, RIMS1, UNC13A, NEDD4L, CPNE5 21 8 9.12 2.53e-05 Up 
Dendrite morphogenesis ADGRB3, CACNA1A, CAMK2B, CTNNA2, DLG4, EPHA4, HPRT1, 
ITPKA, MAP2, PAK3, PPP3CA, CDKL5, NR2E1, CDK5R1, AKAP5, 
RAPGEF2, SEMA3A, BAIAP2, CIT, LZTS1, NEDD4L, MAPK8IP2, 
RBFOX2, NGEF, NSMF, SLITRK5, SHANK1, DCDC2, SHANK3, FMN1 
109 30 5.73 4E-12 Up 
Dendritic shaft CACNA1C, DLG3, DRD1, GRM5, HTR2A, MAP2, PRKAR2B, SLC8A1, 
HOMER1, AKAP5, LZTS1, JPH4, CNIH2 
37 13 8.11 2.07e-07 Up 
Dendritic spine development CAMK2B, DLG4, EPHA4, ITPKA, MEF2C, PAK1, PAK3, CDK5R1, 
NEURL1, BAIAP2, SLC9A6, PLK2, CPEB3, NGEF, SHANK1, SHANK3 
58 16 5.68 4.06e-07 Up 
Dendritic spine membrane ATP2B1, GRIA1, ITGA8, AKAP5, DDN 9 5 18.6 0.000102 Up 
DNA metabolic process BMPR2, CDKN2D, CIDEA, DACH1, HGF, IGF1, KCNK2, KPNA2, 
MAS1, KITLG, ORC4, PAK3, PIK3CA, PRKCG, CHAF1B, CDC7, 
NPM2, PPARGC1A, PARM1, CHD5, UBE2W, FBXW7, TSPYL2, 
BCL11B, SLF1, TBRG1, MAEL, XRCC6BP1, ZBED9, KLHDC3, STOX1, 
KIAA2022 
867 32 0.549 0.000264 Up 
Ensheathment of neurons MYRF, LPAR1, KCNJ10, KEL, MAG, MAL, NGFR, CLDN11, PMP22, 
POU3F2, KLK6, CNTN2, QKI, ARHGEF10, OLIG2, NDRG1, SIRT2, 
PARD3, FA2H, SH3TC2, JAM3, NKX6-2, SERINC5 
101 23 7.53 4.57e-12 Down 
Excitatory postsynaptic potential DLG4, PTK2B, GRIK5, GRIN2A, GRIN2B, MEF2C, PPP3CA, SNCA, 
STX1A, DGKI, NRXN1, RIMS2, RAB3GAP1, RIMS1, MAPK8IP2, 
SHANK1, CELF4, SLC17A7, NETO1, SHANK3 
50 20 9.99 7.46e-12 Up 
GABA receptor activity GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRB2, GABRB3, 
GABRD, GABRG3, GABBR2 
22 10 12.6 2.77e-07 Up 
GABA receptor binding GABRA5, AKAP5, ARFGEF2, JAKMIP1 14 4 6.03 0.0091 Up 
Glial cell development MYRF, GSN, KCNJ10, NKX2-2, POU3F2, CNTN2, ARHGEF10, NDRG1, 
SIRT2, PHGDH, PARD3, FA2H, SH3TC2, NKX6-2 
71 14 6.19 4.84e-07 Down 
Glutamate receptor activity PTK2B, GRIA1, GRIA2, GRIA3, GRIK5, GRIN2A, GRIN2B, GRM1, 
GRM5, GRM8, GRIN3A 
27 11 10.4 2.72e-07 Up 
Innervation GABRA5, GABRB2, GABRB3, PRKCG, NRP1, SEMA3A, UNC13A 23 7 6.47 0.000412 Up 
Inositol phosphate metabolic 
process 
PTK2B, ITPKA, MAS1, OCRL, SNCA, INPP4B, SYNJ1, PPIP5K1, 
PLCH1, PLCB1, NUDT11 
65 11 3.02 0.00247 Up 
Ionotropic glutamate receptor 
activity 
PTK2B, GRIA1, GRIA2, GRIA3, GRIK5, GRIN2A, GRIN2B, GRIN3A 19 8 11 9.08e-06 Up 
JNK cascade ADORA2B, EPHA4, PTK2B, FGF14, MAP3K9, MAP3K10, GADD45B, 
PAK1, PARK2, MAPK9, CCL19, MAP2K4, MAP3K6, RB1CC1, 
RASGRP1, PLCB1, MAPK8IP2, KIAA1804, DUSP19, ZNF675, MAGI3 
185 21 1.9 0.00716 Up 
Lipid binding ABCA1, ANXA5, APOD, AR, C3, LPAR1, HSD17B10, HIP1, HSPA2, 
KCNJ2, MAL, MYO1E, NPC1, P2RX7, PLD1, PTGS1, SELL, SNX1, 
ACOX2, IQGAP1, HIP1R, CYTH1, STARD3, FNBP1, RASGRP3, 
LDLRAP1, GLTP, ANKFY1, PXK, ADAP2, PARD3, PREX1, WDFY4, 
PLEKHF1, PRAM1, PAQR8, MVB12B, SNX29, SYTL4, ARAP1, 
FRMPD2, AMER2, NCF1C, C8orf44-SGK3 
601 44 2.07 2.63e-05 Down 
Mrna processing LGALS3, CELF2, PPARGC1A, CELF3, CPEB3, RBFOX2, RBFOX1, 
MTPAP, CELF4, CELF5, SRRM4, LSM11, RBFOX3 
417 13 0.466 0.00202 Up 
Myelin maintenance MYRF, NDRG1, FA2H, SH3TC2 11 4 14.2 0.000601 Down 
Myelin sheath CA2, CNP, CRYAB, GSN, HSPA2, MAG, MOBP, MOG, MYO1D, 
CLDN11, RDX, CNTN2, NDRG1, SIRT2, PHGDH, GJC2, ERMN, 
MYH14, JAM3, SERINC5 
156 20 3.77 2.29e-06 Down 
Myelination MYRF, LPAR1, KCNJ10, KEL, MAG, MAL, NGFR, PMP22, POU3F2, 
KLK6, CNTN2, QKI, ARHGEF10, OLIG2, NDRG1, SIRT2, PARD3, 
FA2H, SH3TC2, JAM3, NKX6-2, SERINC5 
98 22 7.38 1.81e-11 Down 
Negative regulation of neuron 
apoptotic process 
CACNA1A, PTK2B, GABRA5, GABRB2, GABRB3, MEF2C, PARK2, 
PIK3CA, PRKCG, CCL2, SNCB, SNCA, STAR, STXBP1, NRP1, CHL1, 
PPARGC1A, OXR1, AGAP2 
128 19 2.59 0.000465 Up 





















































































































Negative regulation of 
transcription, DNA-templated 
ARNTL, RUNX1T1, CRYM, CYP1B1, DACH1, FGF9, FOXG1, H2AFZ, 
MEF2C, MAP3K10, TRIM37, PDE2A, RARA, RORB, SATB1, SNCA, 
SOX5, TBX15, THRB, NR2E1, WNT10B, CDK5R1, LRRFIP1, ZBTB33, 
BASP1, ZBTB18, KLF12, CPEB3, PLCB1, SATB2, NEDD4L, SIRT5, 
RBFOX2, ATAD2, TAGLN3, BCL11A, FEZF2, SMYD2, PRDM8, 
TENM2, MTA3, SCRT1, MAEL, PRICKLE1, EID2, ARX, ZNF675, 
KCTD1 
1135 48 0.632 0.00083 Up 
Neuron apoptotic process CACNA1A, EPHA7, PTK2B, GABRA5, GABRB2, GABRB3, GRIK5, 
KCNB1, MEF2C, PAK3, PARK2, PIK3CA, PRKCG, SCN2A, CCL2, 
SNCB, SNCA, STAR, STXBP1, NRP1, CDK5R1, CHL1, PPARGC1A, 
NSMF, OXR1, FBXW7, AGAP2, SDIM1 
206 28 2.35 0.000117 Up 
Neuron spine DLG4, DRD1, EPHA4, GRIA1, GRM5, ITPKA, MYH10, NRGN, 
PRKAR2B, SLC8A1, CDK5R1, NEURL1, DGKI, AKAP5, ARHGAP32, 
FRMPD4, BAIAP2, SLC9A6, ARFGEF2, LZTS1, SHANK1, SEPT11, 
ANKS1B, TENM2, DLGAP3, PPP1R9B, SHANK3, CNIH2 
104 28 5.57 3.28e-11 Up 
Neuronal postsynaptic density ADD2, ATP1A1, BMPR2, CAMK2A, CAMK2B, CTNNA2, DLG4, DMTN, 
GAP43, GRIN2B, MAP2, PAK1, PRKCG, BSN, DGKI, DLGAP1, 
HOMER1, BAIAP2, CAP2, CNKSR2, CLSTN1, MAPK8IP2, SHANK1, 
CLSTN2, SHANK3 
64 25 9.69 3.02e-14 Up 
Neuron-neuron synaptic 
transmission 
CA7, CACNA1A, CACNB4, CAMK4, DRD1, PTK2B, GABRA1, GABRB2, 
GLRB, GRIA1, GRIA2, GRIA3, GRIK5, GRIN2A, GRM1, GRM5, GRM8, 
HRH2, HTR1B, HTR2A, MEF2C, NPY5R, PAK1, PARK2, PRKCE, 
PTGS2, SNCA, STXBP1, SYT1, GLRA3, DGKI, DLGAP2, NRXN1, 
RAB3GAP1, UNC13A, MAPK8IP2, RASD2, TMOD2, SHC3, SLC17A7, 
SHANK3, GRIN3A, CNIH2 
136 43 7.06 2.63e-19 Up 
Neurotransmitter secretion CACNA1A, CACNA1B, CAMK2A, GAD1, GLS, GRIK5, MEF2C, PAK1, 
PARK2, PFN2, SLC1A1, SLC1A2, SNCA, STX1A, STXBP1, SYN1, SYN2, 
SYT1, SYT5, DOC2A, PPFIA4, PPFIA2, PPFIA3, CADPS, LIN7A, 
SYNJ1, SYT7, DGKI, BZRAP1, NRXN1, RIMS2, RIMS3, CPLX1, HRH3, 
ADGRL1, RAB3GAP1, RIMS1, UNC13A, PCLO, SYTL2, SLC17A7, 
SYT13, SYT16, SYT12, CADPS2, SNAP47 
154 46 6.52 1.93e-19 Up 
Node of Ranvier KCNQ2, KCNQ3, SCN1A, SCN1B, SCN2A, SCN8A 15 6 9.92 0.000193 Up 
Nucleic acid metabolic process ABCA2, ABL1, PARP4, AR, ATM, BMP8B, MYRF, CAPN3, CAT, CBFB, 
CCNA2, CDKN1C, CENPB, ELF1, EYA4, ERF, FGF1, FGFR2, GDF1, 
HSD17B10, HDAC1, HIP1, HOXA1, HOXA2, HOXA5, HOXB2, HOXB5, 
HOXD1, HOXD3, HSPA1A, FOXN2, JUP, SMAD5, SMAD9, MCM7, 
MEIS1, CIITA, FOXO4, NKX2-2, NOTCH1, YBX1, PBX3, PDE8A, 
ENPP2, POLR2L, POU3F2, PSEN1, RNH1, RPLP0, RPS5, RXRG, 
SALL1, SGK1, SOX10, SREBF1, STAT2, SYK, TAL1, TCF12, TRAF1, 
TRPS1, ZNF3, ZNF69, VEZF1, FZD5, ARHGEF5, HIST1H2AC, 
HIST1H3E, HIST1H4H, HIST1H4B, RNASET2, CCNE2, QKI, LITAF, 
ST18, ZNF536, DDX39A, OLIG2, HMG20B, SEMA4D, TXNIP, DMRT2, 
TCFL5, ATF7, IKZF2, ZNF652, SIRT2, SAMD4A, KANK1, HEY2, 
BAMBI, ZNF521, ZBTB20, GREM1, CECR2, HIPK2, KLF15, BAZ2B, 
SLC40A1, SOX8, ZBTB7B, RRNAD1, KLF3, DDIT4, ZNF280D, TRIM62, 
CHD7, SLF2, ZNF83, SLC2A4RG, OTUD7B, BBX, MAVS, SFMBT2, 
NCOA5, TP53INP2, ZNF462, ARHGAP22, CREB3L2, CRTC3, TRAK2, 
BHLHE41, DBF4B, TSC22D4, NKX6-2, ZBTB37, LOXL3, OLIG1, 
ZSWIM7, GABPB2, CC2D1B, ZBTB12, ZNF844, ZNF326, FRYL, 
C9orf142, ZNF710, GTF2IRD2B, DBX2, HIST2H4B, ZNF812, 
TMEM229A, GTF2H2C_2, C8orf44-SGK3 
4679 144 0.718 0.000284 Up 
Oligodendrocyte development MYRF, GSN, KCNJ10, NKX2-2, CNTN2, FA2H, NKX6-2 32 7 6.99 0.000187 Down 
Oligodendrocyte differentiation BOK, MYRF, CNP, GSN, KCNJ10, NKX2-2, NOTCH1, SOX10, CNTN2, 
OLIG2, SOX8, FA2H, NKX6-2 
75 13 5.27 5.64e-06 Down 
Phosphatase activity ALPL, ATP1A1, CDKN3, DUSP8, OCRL, PPP2R5D, PPP3CA, PPP3CB, 
PPP3R1, MAP2K1, PTPN3, PTPN4, PTPRN2, PTPRR, INPP4B, SYNJ1, 
PPIP5K1, LPPR4, PTPRT, PTP4A3, NT5DC3, PDP1, LPPR3, PTPN5, 
DUSP19, PPM1L, PPM1J 
254 27 1.81 0.00475 Up 
Phosphatidylinositol binding HIP1, KCNJ2, MYO1E, PLD1, SNX1, IQGAP1, HIP1R, LDLRAP1, 
ANKFY1, PXK, ADAP2, PARD3, PLEKHF1, SNX29, ARAP1, FRMPD2, 
AMER2, NCF1C, C8orf44-SGK3 
187 19 2.92 9.82e-05 Down 






















































































































protein coupled receptor signaling 
pathway 
ADRA1B, CCKBR, CHRM1, CHRM3, DRD1, GRM1, GRM5, HRH2, 
HTR2A, OPRK1, OPRM1, HOMER1, MCHR2 
81 13 2.84 0.00172 Up 
Phospholipid binding ABCA1, ANXA5, LPAR1, HIP1, KCNJ2, MYO1E, PLD1, SNX1, IQGAP1, 
HIP1R, LDLRAP1, ANKFY1, PXK, ADAP2, PARD3, PREX1, WDFY4, 
PLEKHF1, SNX29, SYTL4, ARAP1, FRMPD2, AMER2, NCF1C, 
C8orf44-SGK3 
332 25 2.1 0.000966 Down 
Phospholipid translocation ABCA1, P2RX7, ATP10B, ATP11A 20 4 6.21 0.00667 Down 
Positive regulation of RNA 
metabolic process 
ACVR1B, ARNTL, BMPR2, CAMK4, CAMK2A, CDH13, ETV1, H2AFZ, 
HGF, IGF1, KRAS, LUM, MEF2C, TRIM37, PPP1R12A, NEUROD2, 
PARK2, PLAGL1, PPP3CA, PPP3CB, PPP3R1, PRKCB, MAPK9, 
MAP2K1, RARA, RORB, SOX5, STAT4, THRB, NR2E1, TRAF5, 
WNT10B, ITGA8, LMO4, LDB2, LHX2, MICAL2, CAMKK2, TBR1, 
PPARGC1A, MLLT11, CELF3, KLF12, CPEB3, MAPRE3, DDN, PLCB1, 
SATB2, ATAD2, BCL11A, TESC, FEZF2, FBXW7, DCAF6, CELF4, 
ARNTL2, ATXN7L3, CAMK1D, MKL2, NEUROD6, BCL11B, CSRNP3, 
MED12L, RHEBL1, MTPN, SOHLH1 
1455 66 0.678 0.0011 Up 
Postsynapse ADD2, ATP1A1, BMPR2, CACNA1C, CAMK2A, CAMK2B, CHRM1, 
CHRM3, CTNNA2, DLG3, DLG4, DRD1, DMTN, EPHA4, EPHA7, 
PTK2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRB2, 
GABRB3, GABRD, GABRG3, GAP43, GLRB, GRIA1, GRIA2, GRIA3, 
GRIK5, GRIN2A, GRIN2B, GRM1, GRM5, ITPKA, ITPR1, KCNB1, 
KCNC2, KCNJ4, KCNMA1, MAP2, MYH10, NRGN, PAK1, PRKAR2B, 
PRKCG, SLC8A1, GLRA3, KCNAB2, ITGA8, LIN7A, CDK5R1, BSN, 
NEURL1, DGKI, DLGAP2, DLGAP1, HOMER1, CABP1, AKAP5, 
GABBR2, ARHGAP32, FRMPD4, LZTS3, BAIAP2, CAP2, ARFGEF2, 
LZTS1, CNKSR2, CLSTN1, RIMS1, SYNE1, NCS1, MAPK8IP2, NSMF, 
PCLO, SHANK1, SEPT11, ANKS1B, TENM2, LRFN2, KCTD16, LRRC7, 
DLGAP3, CACNG8, CLSTN2, LRRTM4, NETO1, PPP1R9B, SHANK3, 
CADPS2, GRIN3A, GRASP, CNIH2, LRRTM1, LRRTM3, IQSEC3 
341 98 6.47 7.81e-39 Up 
Postsynaptic membrane CHRM1, CHRM3, DLG3, DLG4, EPHA4, EPHA7, GABRA1, GABRA2, 
GABRA3, GABRA4, GABRA5, GABRB2, GABRB3, GABRD, GABRG3, 
GLRB, GRIA1, GRIA2, GRIA3, GRIK5, GRIN2A, GRIN2B, KCNB1, 
KCNC2, KCNJ4, KCNMA1, GLRA3, LIN7A, NEURL1, DLGAP2, 
DLGAP1, HOMER1, CABP1, GABBR2, ARHGAP32, LZTS3, LZTS1, 
CNKSR2, CLSTN1, SYNE1, NCS1, NSMF, SHANK1, ANKS1B, TENM2, 
LRFN2, KCTD16, LRRC7, DLGAP3, CACNG8, CLSTN2, LRRTM4, 
NETO1, SHANK3, CADPS2, GRIN3A, GRASP, CNIH2, LRRTM1, 
LRRTM3, IQSEC3 
197 61 6.98 1.99e-26 Up 
Potassium channel activity KCNB1, KCNC1, KCNC2, KCND3, KCNF1, KCNH1, KCNJ3, KCNJ4, 
KCNJ6, KCNJ9, KCNK2, KCNMA1, KCNN1, KCNQ2, KCNQ3, KCNS1, 
KCNS2, KCNAB1, KCNAB2, KCNAB3, KCNH4, KCNH3, KCNV1, 
KCNH5, KCNIP2, KCNQ5, KCNT1, KCNK15, KCNIP4, KCNH7, 
KCNG3, KCNT2, HCN1 
119 33 5.93 1.53e-13 Up 
Presynapse DLG4, GABRA2, GRIA1, GRIA2, GRIN2B, ICA1, NPY1R, SNCA, STX1A, 
SYN1, SYN2, SYT1, SYT5, SLC30A3, FZD3, DOC2A, PPFIA4, PPFIA2, 
PPFIA3, BSN, SYT7, SYNGR1, DGKI, RIMS2, RIMS3, SV2B, DNM1L, 
RIMS1, UNC13A, DMXL2, ERC2, PCLO, SVOP, SLC17A7, SYT12, 
TPRG1L, SYNPR, STXBP5, SCAMP5, SLC6A17, UNC13C 
142 41 6.21 5.89e-17 Up 
Presynaptic active zone SYN1, FZD3, PPFIA4, PPFIA2, PPFIA3, BSN, DGKI, RIMS2, RIMS3, 
RIMS1, UNC13A, ERC2, PCLO, SLC17A7, UNC13C 
24 15 25 7.23e-13 Up 
Protein kinase C-activating G-
protein coupled receptor signaling 
pathway 
CCK, CHRM1, DGKB, GAP43, GRM1, GRM5, HTR1B, DGKZ, DGKE, 
DGKI 
32 10 6.74 1.85e-05 Up 
Protein lipidation ABCA1, ZDHHC9, PIGT, HHATL, ZDHHC14, ZDHHC11, MAP6D1, 
ATG4C, PIGM, ZDHHC20 
84 10 3.38 0.00152 Down 
Regulation of axon guidance BMPR2, NRP1, SEMA3A, TBR1, FEZF2 18 5 5.68 0.00441 Up 
Regulation of neuron apoptotic 
process 
CACNA1A, EPHA7, PTK2B, GABRA5, GABRB2, GABRB3, GRIK5, 
KCNB1, MEF2C, PAK3, PARK2, PIK3CA, PRKCG, CCL2, SNCB, 
SNCA, STAR, STXBP1, NRP1, CDK5R1, CHL1, PPARGC1A, NSMF, 
OXR1, FBXW7, AGAP2 
183 26 2.47 9.7e-05 Up 





















































































































Regulation of neurotransmitter 
levels 
DAGLA, CACNA1A, CACNA1B, CAMK2A, DRD1, GABRA2, GAD1, 
GLS, GRIK5, MEF2C, PAK1, PARK2, PDE1B, PFN2, SLC1A1, SLC1A2, 
SNCA, STX1A, STXBP1, SYN1, SYN2, SYT1, SYT5, DOC2A, PPFIA4, 
PPFIA2, PPFIA3, CADPS, LIN7A, SYNJ1, SYT7, DGKI, BZRAP1, 
NRXN1, RIMS2, RIMS3, CPLX1, HRH3, ADGRL1, RAB3GAP1, RIMS1, 
UNC13A, PCLO, SYTL2, SLC17A7, SYT13, SYT16, SYT12, CADPS2, 
SNAP47 
192 50 5.4 3.37e-18 Up 
Regulation of postsynaptic 
membrane potential 
DLG4, PTK2B, FGF14, GABRB3, GRIK5, GRIN2A, GRIN2B, MEF2C, 
PPP3CA, SNCA, STX1A, DGKI, NRXN1, RIMS2, RAB3GAP1, RIMS1, 
MAPK8IP2, SHANK1, CELF4, SLC17A7, NETO1, SHANK3 
59 22 8.92 3.58e-12 Up 
Regulation of synaptic plasticity ATP2B2, CAMK2A, CAMK2B, DLG4, DRD1, PTK2B, FGF14, GRIA1, 
GRIN2A, GRIN2B, GRM5, HRH2, ITPKA, KCNB1, MEF2C, NEUROD2, 
NRGN, PAK1, PPP3CB, PTGS2, PTN, SNCA, STAR, STXBP1, NR2E1, 
PPFIA3, SYNGAP1, SYNGR1, NEURL1, DGKI, RAPGEF2, BAIAP2, 
PLK2, CPEB3, RAB3GAP1, RIMS1, UNC13A, NSMF, NPTN, JPH3, 
NETO1, JPH4, SHANK3, SNAP47, CNTN4, LRRTM1 
132 46 8.2 1.48e-22 Up 
Regulatory region nucleic acid 
binding 
ARNTL, ETV1, H2AFZ, HIVEP2, MEF2C, NEUROD2, PLAGL1, RARA, 
SATB1, SNCA, SOX5, STAT4, TBX15, LMO4, ZBTB33, BASP1, TBR1, 
KLF12, DDN, BCL11A, FEZF2, ARNTL2, PKNOX2, DMRTC1, 
NEUROD6, BCL11B, ZNF831, ZNF519, ARX, ZNF675, STOX1, 
SOHLH1, DMRTC1B 
790 33 0.643 0.00634 Down 
Release of cytochrome c from 
mitochondria 
CCK, IFI6, HGF, IGF1, PARK2, MAPK9, HRK, DNM1L, MLLT11, 
GGCT 
55 10 3.29 0.00222 Up 
SNARE binding CACNA1A, STX1A, STXBP1, SYT1, SYT5, DOC2A, NAPG, SYT7, 
STXBP5L, CPLX1, UNC13A, SYTL2, SYT13, NAPB, SYT16, SYT12, 
SNAP47, STXBP5 
112 18 2.91 0.000188 Up 
Sodium channel activity SHROOM2, SCN1A, SCN1B, SCN2A, SCN2B, SCN8A, SCN3B, HCN1 36 8 4.32 0.00141 Up 
Synapse ADD2, ATP1A1, ATP2B1, ATP2B2, BMPR2, CACNA1C, CACNB4, 
CAMK2A, CAMK2B, CAMK2D, CCK, CHRM1, CHRM3, AP1S1, 
CTNNA2, DLG3, DLG4, DRD1, DMTN, EPHA4, EPHA7, PTK2B, 
GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRB2, GABRB3, 
GABRD, GABRG3, GAP43, GLRB, GRIA1, GRIA2, GRIA3, GRIK5, 
GRIN2A, GRIN2B, GRM1, GRM5, GRM8, ICA1, ITPKA, ITPR1, KCNB1, 
KCNC2, KCNH1, KCNJ4, KCNMA1, MAP2, MYH10, NPY1R, NRCAM, 
NRGN, OPRK1, PAK1, PDE2A, PFN2, PRKAR2B, PRKCG, PTPRN2, 
CCL2, SLC8A1, SNCB, SNCA, STX1A, STXBP1, SYN1, SYN2, SYT1, 
SYT5, SLC30A3, FZD3, GLRA3, DOC2A, PRSS12, PPFIA4, PPFIA2, 
KCNAB2, ITGA8, PPFIA3, CADPS, LIN7A, CDK5R1, BSN, WASF1, 
SYT7, SYNGR1, NEURL1, DGKI, DLGAP2, DLGAP1, NRXN1, 
HOMER1, CABP1, AKAP5, GABBR2, RAPGEF2, RIMS2, ARHGAP32, 
FRMPD4, LZTS3, RIMS3, SV2B, DNM1L, OLFM1, BAIAP2, SLC9A6, 
CAP2, ARFGEF2, CPLX1, LZTS1, AAK1, CPEB3, ADGRL1, CNKSR2, 
CLSTN1, RIMS1, PDZRN3, UNC13A, NMNAT2, DDN, DMXL2, SYNE1, 
NCS1, MAPK8IP2, FRRS1L, MYRIP, NSMF, ERC2, CYFIP2, NPTN, 
PCLO, PACSIN1, SHANK1, NRN1, SVOP, SEPT11, SEPT3, ANKS1B, 
SLC17A7, TENM2, TBC1D24, LRFN2, KCTD16, LRRC7, DLGAP3, 
CACNG8, CLSTN2, LRRTM4, NETO1, PPP1R9B, SHANK3, SYT12, 
CADPS2, PRRT2, GRIN3A, OLFM3, TPRG1L, SYNPR, STXBP5, CBLN4, 
GRASP, SCAMP5, PHACTR1, CNIH2, LRRTM1, LRRTM3, VWC2, 
SLC6A17, IQSEC3, UNC13C 
658 173 6.11 1.15e-62 Up 
Synapse maturation CAMK2B, NEUROD2, NEURL1, NRXN1, ADGRL1, SHANK1 18 6 7.39 0.000626 Up 
Synaptic transmission ADCY1, ATP2B2, CA7, CACNA1A, CACNA1B, CACNA1C, CACNB1, 
CACNB2, CACNB4, CAMK4, CAMK2A, CAMK2B, CAMK2D, CHRM1, 
CHRM3, DLG3, DLG4, DRD1, EGR3, PTK2B, FGF14, GABRA1, 
GABRA2, GABRA3, GABRA4, GABRA5, GABRB2, GABRB3, GABRD, 
GABRG3, GAD1, GLRB, GLS, GNAI3, GRIA1, GRIA2, GRIA3, GRIK5, 
GRIN2A, GRIN2B, GRM1, GRM5, GRM8, HRH2, HTR1B, HTR1E, 
HTR1F, HTR2A, ITPKA, KCNB1, KCNC1, KCNC2, KCND3, KCNF1, 
KCNH1, KCNJ3, KCNJ4, KCNJ6, KCNJ9, KCNK2, KCNMA1, KCNN1, 
KCNQ2, KCNQ3, KCNS1, KCNS2, KIF5A, MEF2C, MYO5A, 
NEUROD2, NPY5R, OPRK1, OPRM1, PAK1, PARK2, PFN2, PPP3CA, 
PPP3CB, PRKCB, PRKCE, PRKCG, PTGS2, PTN, RIT2, SCN1B, 
SCN2B, CCL2, SLC1A1, SLC1A2, SNCB, SNCA, SSTR2, SSTR4, STAR,
702 184 6.18 1.54e-66 Up 








































Sixty-six genes from different pathways were selected 
for validation by RT-qPCR. 
 
Inflammatory gene expression in the anterior horn 
of the spinal cord 
 
No modifications in the expression levels of glial 
fibrillary acidic protein gene (GFAP) or prostaglandin-
endoperoxide synthase 2 gene (PTGS2) occurred in 
ALS when compared with controls (p=0.31 and p=0.55, 
respectively). However, expression levels of AIF1 and 
CD68 were significantly increased in the anterior horn 
of the spinal cord in ALS (p=0.044 and p=0.00023, 
respectively). Gene expression of toll-like receptors 
(TLRs) TLR2, TLR and TLR7 was significantly 
increased in the spinal cord in ALS cases (p=2.48E-05, 






































not (p=0.669). IL1B was up-regulated (p=0.005), but 
IL6 and IL6ST were not (p=0.26 and p=0.76, 
respectively). In contrast, the expression of IL10 and its 
corresponding receptors IL10RA and IL10RB was 
increased in ALS (p=0.00046, p=0.022 and p=3.23E-05,  
respectively). TNFA expression was significantly 
increased whereas a trend was found for TNFRSF1B 
(p=0.04 and p=0.08, respectively). The expression of 
CTSC and CTSS was significantly increased in spinal 
cord in ALS (p=5.82204E-05 and p=0.00014, 
respectively). Levels of SLC11A1 were also 
significantly increased in spinal cord of ALS (p=0.014). 
HLA-DRB1, a protein coding gene for the Major 
Histocompatibility Complex Class II (MHC-II) DR β1 
protein was markedly up-regulated in ALS (p=0.004365). 
 
PDCD1LG2, IFNγ and IL33 were significantly up-
regulated in the anterior horn of the spinal cord in ALS 
(p=0.00153, p=0.03 and p=0.0032, respectively).  




  STX1A, STXBP1, SYN1, SYN2, SYT1, SYT5, NR2E1, VIPR1, KCNAB1, 
GLRA3, DOC2A, PPFIA4, PPFIA2, KCNAB2, PPFIA3, CADPS, LIN7A, 
SYNGAP1, SYNJ1, BSN, SYT7, SYNGR1, NEURL1, DGKI, KCNAB3, 
DLGAP2, DLGAP1, BZRAP1, NRXN1, HOMER1, AKAP5, GABBR2, 
RAPGEF2, RIMS2, RIMS3, SNAP91, CACNG3, BAIAP2, CSPG5, PLK2, 
CPLX1, HRH3, CPEB3, ADGRL1, CLSTN1, RAB3GAP1, RIMS1, 
UNC13A, PLCB1, KCNH4, KCNH3, MAPK8IP2, RASD2, NSMF, 
SLITRK5, KCNV1, NPTN, KCNH5, PCLO, TMOD2, KCNIP2, SHANK1, 
SHC3, SYTL2, PCDHB13, KCNQ5, CELF4, SLC17A7, JPH3, SYT13, 
CACNG8, CLSTN2, NETO1, SYT16, CAMKK1, JPH4, PPP1R9B, 
SHANK3, KCNH7, SYT12, CADPS2, BTBD9, GRIN3A, SNAP47, CNTN4, 
KCNG3, CNIH2, LRRTM1, HCN1, UNC13C 
     
Synaptic transmission, 
glutamatergic 
CACNA1A, CACNB4, DRD1, PTK2B, GRIA1, GRIA2, GRIA3, GRIK5, 
GRIN2A, GRM1, GRM5, GRM8, HTR1B, HTR2A, MEF2C, PAK1, 
PARK2, PTGS2, SYT1, DGKI, NRXN1, RAB3GAP1, UNC13A, 
MAPK8IP2, SHC3, SLC17A7, SHANK3, GRIN3A, CNIH2 
78 29 8.94 1.42e-15 Up 
Synaptic vesicle exocytosis GRIK5, PFN2, STX1A, STXBP1, SYN1, SYT1, SYT5, DOC2A, CADPS, 
SYNJ1, SYT7, RIMS3, CPLX1, ADGRL1, RIMS1, UNC13A, PCLO, 
SYTL2, SYT13, SYT16, SYT12, CADPS2, SNAP47 
76 23 6.51 1.59e-10 Up 
Synaptic vesicle localization FGF14, GRIK5, PARK2, PFN2, SH3GL2, SNCA, STX1A, STXBP1, SYN1, 
SYT1, SYT5, AP3B2, DOC2A, CADPS, LIN7A, SYNJ1, SYT7, NRXN1, 
RIMS3, CPLX1, ADGRL1, RIMS1, UNC13A, PCLO, PACSIN1, SYTL2, 
SYT13, SYT16, SYT12, CADPS2, BTBD9, SNAP47 
120 32 5.49 1.97e-12 Up 
Synaptic vesicle membrane ICA1, STX1A, SYN1, SYN2, SYT1, SYT5, SLC30A3, DOC2A, SYT7, 
SYNGR1, SV2B, DNM1L, DMXL2, SVOP, SLC17A7, SYT12, SYNPR, 
SCAMP5, SLC6A17 
55 19 7.94 4.52e-10 Up 
Synaptic vesicle priming STX1A, STXBP1, CADPS, SYNJ1, CADPS2, SNAP47 12 6 14.8 4.34e-05 Up 
Synaptic vesicle recycling FGF14, SH3GL2, SNCA, SYT1, SYT5, SYNJ1, PACSIN1, BTBD9 29 8 5.64 0.000338 Up 
Synaptic vesicle transport FGF14, GRIK5, PARK2, PFN2, SH3GL2, SNCA, STX1A, STXBP1, SYN1, 
SYT1, SYT5, AP3B2, DOC2A, CADPS, LIN7A, SYNJ1, SYT7, RIMS3, 
CPLX1, ADGRL1, RIMS1, UNC13A, PCLO, PACSIN1, SYTL2, SYT13, 
SYT16, SYT12, CADPS2, BTBD9, SNAP47 
116 31 5.51 4.11e-12 Up 
Syntaxin binding CACNA1A, STXBP1, SYT1, SYT5, DOC2A, NAPG, SYT7, STXBP5L, 
CPLX1, UNC13A, SYTL2, SYT13, NAPB, SYT16, SYT12, SNAP47, 
STXBP5 
78 17 4.24 4.82e-06 Up 
Terminal bouton CCK, AP1S1, GRIK5, GRIN2A, KCNC2, KCNMA1, PFN2, PTPRN2, 
SNCA, STXBP1, SYN1, PRSS12, SYT7, SYNGR1, CPLX1, AAK1, 
TBC1D24 
61 17 5.8 1.39e-07 Up 




































Finally, IL8 (interleukin 8) and ITGB4 (integrin 
subunit beta 4) expression was similar in control and 
ALS cases (p=0.92 and p=0.40, respectively) (Figure 
3).  
 
Axonemal gene expression in anterior horn of the 
spinal cord  
 
No modifications in the expression levels of NEFH, 
which codes for neurofilament heavy polypeptide 
protein, was seen in ALS when compared with 
controls (p=0.30). However, DNAAF1 levels were 
significantly reduced (p=0.019). Expression of 
DNAH2, DNAH5, DNAH7 and DNAH11 mRNA was 
significantly reduced in ALS (p=0.029, p=0.012, 
p=0.005 and p=0.023, respectively), whereas DNAH9 
mRNA was not altered (p=0.14). DNAI1 mRNA 
expression was also significantly reduced in ALS 



































SLC1A2 and SC17A7 expression in anterior horn of 
the spinal cord 
 
SLC1A2 and SLC17A7 expression levels were 
significantly decreased in the anterior horn of the spinal 
cord in ALS anterior (p=0.000115 and p=0.000125, 
respectively). See Figure 3.  
 
Neurotransmission-related gene expression in 
frontal cortex area 8  
 
GRIA1, which codes for the ionotropic glutamate 
receptor AMPA 1, and GRIN2A and GRIN2B, coding 
for NMDA receptors, were significantly up-regulated 
(p=0.018, p=0.018 and p=0.029, respectively) in frontal 
cortex in ALS cases. GRM5, which codes for the 
glutamate metabotropic receptor 5, was also up-
regulated (p=0.0079). However, no significant alteration 






















































































































components. Up of AIGF1 and CD68,  toll‐like  receptors,  cytokines and  receptors,  chemokines and other mediators of  the  innate and
adaptative inflammatory responses. Axolemal genes, excepting NEFH, which shows a non‐significant trend to decrease, are significantly
down‐regulated.  (E) glutamate transporter coding genes. The significance level is set at * p < 0.05, ** p < 0.01 and *** p < 0.001.         
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Regarding the GABAergic system, GAD1 was up-
regulated in ALS (p=0.034). Gene expression of GABA 
receptors GABRA1, GABRD, GABRB2 was increased 
(p=0.09, tendency, p=0.006 and p=0.0029, 
respectively). GABBR2 mRNA levels were also 
significantly elevated in the frontal cortex in ALS 


















































Synaptic cleft gene expression in frontal cortex area 8 
 
BSN, which codes for Bassoon, a pre-synaptic 
cytoskeletal matrix, was up-regulated in ALS (p=0.04). 
mRNA levels of PCLO, coding gene for Piccolo protein, 
and FRMPD4 were also increased in ALS (p=0.036 and 


















































Figure 4. mRNA expression  levels of  selected deregulated genes  identified by microarray analysis  in  frontal  cortex area 8 of ALS
cases  determined  by  TaqMan  RT‐qPCR  assays.  (A)  oligodendroglial  and myelin‐related  genes;  (B)  glutamatergic  and  GABAergic‐
related genes and corresponding ionotropic and metabotropic receptors; (C) genes coding for synaptic cleft proteins. Significant up of
genes  linked  to  neurotransmission  and  synapses,  and  significant  down  of  genes  linked  to  oligodendroglia  and myelination.  (D)
Glutamate transporter coding genes. The significance level is set at * p < 0.05, ** p < 0.01 and *** p < 0.001, and tendencies at # < 0.1.  
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neuritin 1, but not DDN, which codes for dendrin protein, 
was up-regulated in the frontal cortex in ALS (p=0.04 
and p=0.92, respectively) (Figure 4).  
 
Myelin- and oligodendrocyte-related gene expression 
in frontal cortex area 8 
 
Significant decrease in mRNA expression of myelin 
transcription factor (MYRF) (p= 0.028), OLIG2 














































transferring (TF) (p=0.5), proteolipid protein 1 (PLP1) 
(p=0.040), myelin basic protein (MBP) (p=0.061), 
myelin-associated oligodendrocyte basic protein 
(MOBP) (p=0.019), oligodendrocyte glycoprotein 
(MOG) (p=0.05), Mal T-cell differentiation protein 
(MAL) (p=0.039), myelin associated glycoprotein 
(MAG) (p=0.035), and 2',3'-cyclic nucleotide 3' 
phosphodiesterase (CNP1) (p=0.017) was seen in 




















































68, HLA‐DRB1, and HLA‐DRB5 antibodies. VDAC  immunoreactivity  is decreased whereas  IL‐10 and TNF‐α  is  increased  in  remaining
motor neurons in sALS. SLC1A2 immunoreactivity is reduced in the membrane of neurons and in neuropil of the anterior horn in sALS.
Paraffin sections, slightly counterstained with haematoxylin; a, c‐d, o‐t, bar in t = 40μm; e‐n, bar in = 20μm; bar in b = 10μm.     
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SLC1A2 and SLC17A7 expression in frontal cortex 
area 8 
 
SLC1A2 expression was significantly increased 
(p=5.25e-5) whereas SLC17A7 mRNA showed a non-
significant increase (p=0.42) in frontal cortex area 8 in 
ALS (Figure 4).   
  
Immunohistochemistry in spinal cord 
 
The anterior horn of the spinal cord in ALS cases 
showed decreased number of neurons  and  altered  mor- 
phology of most remaining motor neurons including 
loss of endoplasmic reticulum (chromatolysis) and 
axonal ballooning (Figure 5a) and intracytoplasmic 
TDP-43-immunoreactive inclusions (Figure 5b). 
Immunohistochemistry was carried out in the lumbar 
spinal cord in control and sALS cases (Figure 5a and b). 
VDAC was reduced in a subpopulation of neurons in 
the anterior horn in ALS, but not in neurons of the 
Clarke’s column and posterior horn, when compared 
with controls (Figure 5c and d). Increased expression of 
GFAP was found in reactive astrocytes in the lateral 
columns and anterior horn of the spinal cord in ALS 
































regarding microglial cell markers: IBA-1 and CD68 
immunoreactivity was dramatically increased in the 
pyramidal tracts and anterior horn in ALS; moreover the 
morphology of microglia was modified in pathological 
cases with predominance of round, amoeboid microglia 
(Figure 5g-j). Similar immunoreactivity, distribution 
and morphology were found in reactive microglia using 
antibodies against HLA-DRB1 and HLA-DRB5 (Figure 
5k-n). In contrast IL-10 and TNF-α immunoreactivity 
predominated in neurons; immunoreactivity was 
increased in neurons in ALS cases compared with 
controls (Figure 5o-r). Finally, GluT (SLC1A2), the 
transporter of glutamate from the extracellular space at 
synapses, was expressed in the membrane of neurons 
and in the neuropil; SLC1A2 immunoreactivity was 
decreased in neurons and neuropil  of  the  anterior  horn  
in ALS (Figure 5s, t).    
 
Gel electrophoresis and western blotting in frontal 
cortex area 8 
 
A few tested antibodies were eventually suitable for 
western blotting studies. No differences in the 
expression levels of glutamate receptor ionotropic, 
































amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic  acid  receptor  1  (GluR‐1),  glutamate  decarboxylase  1  (GAD1)
and gamma‐aminobutyric acid receptor subunit beta‐2  (GABAAB2)  in  the  frontal cortex area 8 of control and
ALS. Significant increased levels of GluR‐1 and a tendency to increased levels of GABAAB2 are seen in ALS when
compared with controls. The significance level is set at ** p < 0.01 and tendencies at # < 0.1. 
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1 (GAD1) were observed between control and ALS 
cases. However, a significant increase in α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor 1 
(AMPAR GluR-1) ** p < 0.01 and a tendency to 
increase in the expression of gamma-aminobutyric acid 
receptor subunit beta-2 (GABAAB2) (#  p < 0.1) was 
found in the frontal cortex in ALS when compared to 




Transcriptomic profiles in ALS are region-dependent 
when comparing the anterior horn of the lumbar spinal 
cord and frontal cortex area 8 in the same individuals. 
As an important regional difference related to 
excitotoxicity, the expression of glutamate transporters 
is markedly different in the anterior horn of the spinal 
cord and the frontal cortex area 8. SLC1A2 and 
SLC17A7 mRNA expression is significantly decreased 
in the anterior horn of the spinal cord, whereas SLC1A2 
is significantly increased in frontal cortex area 8. 
SLC1A2 encodes the solute carrier family 1 member 2 
or excitatory amino-acid transporter 2 (EAAT2) which 
clears glutamate from the extracellular space at synapses 
in the central nervous system. Immunohistochemistry 
has shown decreased SLC1A2 protein expression in the 
membrane of neurons and neuropil of the anterior horn 
in ALS. SLC17A7 encodes the vesicular glutamate 
transporter 1 (VGLUT1) which is a vesicle-bound, 
sodium-dependent phosphate glutamate transporter 
expressed in the synaptic vesicles. Decreased 
expression of these proteins is linked to increased 
excitotoxity which is postulated as primary factor 
triggering motor neuron degeneration in ALS [30, 31].    
 
Whole transcriptome arrays show that major up-
regulated clusters in the anterior horn are related with 
innate inflammatory and adaptative inflammatory 
responses. Genes involved in hemostasis and ion 
transport forms a small up-regulated group. The major 
group of down-regulated genes is linked to the neuronal 
cytoskeleton. The majority of significantly differentially 
up-regulated transcripts in sALS in frontal cortex area 
8, as revealed by whole transcriptome arrays, code for 
proteins linked with neurotransmission, ion channels 
and ion transport, synapses, and axon and dendrite 
maintenance, whereas down-regulated genes code for 
proteins involved in oligodendrocyte development and 
function, myelin regulation and membrane lipid 
metabolism.  
 
Altered gene expression as revealed by whole 
transcriptome arrays has been validated by RT-qPCR in 
58 of 66 assessed genes. These observations increase 
the list of genes which are de-regulated in the anterior 
spinal cord and provide, for the first time, robust 
evidence of gene de-regulation in frontal cortex area 8 
in sALS. Increased inflammatory response in the 
anterior horn and increased expression of selected 
neurotransmitter markers in frontal cortex has been 
further assessed using immunohistochemistry and 
western blotting, respectively.  
 
Inflammation in the anterior horn of the spinal cord  
 
AIF1 gene codes for the Allograft Inflammatory Factor 
1, a protein induced by cytokines and interferon which 
promotes macrophage and glial activation [32, 33]. 
CD68 codes for the macrophage antigen CD68 
glycoprotein which is expressed by microglial cells [35-
37], the principal resident immune cell population in 
brain [38, 39]. Microglia pro-inflammatory state 
activation can be initiated by engagement of germline-
encoded pattern-recognition receptors such as Toll-like 
receptors (TLRs) which are expressed in glial cells [40]. 
TLR activation, in turn, activates phagocytosis [41-43] 
and pro-inflammatory responses [44]. Up-regulated 
interleukins in ALS are IL1B, the coding gene for 
interleukin 1B an important mediator of the inflam-
matory response [45], interleukin 10 (encoded by IL10) 
which has pleiotropic effects down-regulating the 
expression of Th1 cytokines, MHC class II antigens and 
co-stimulating the production of several molecules by 
macrophages through the activation of IL10 receptor 
subunit α and subunit β (encoded by IL10RA and 
IL10RB, respectively) [46]. However, IL6 mRNA, 
which encodes a specific pro-inflammatory cytokine 
with regenerative and anti-inflammatory activities in 
particular settings [47-50] is not modified. Tumor 
Necrosis Factor Receptor Superfamily Member 1A 
(encoded by TNFA) is involved in the regulation of a 
wide spectrum of biological processes including cell 
proliferation, cell differentiation, apoptosis, lipid 
metabolism and coagulation [50, 51]. CTSC gene 
encodes Cathepsin C which is central coordinator of 
activation of many serine proteinases in immune cells 
[52]. CTSS codes for a protein of the same family, 
Cathepsin S, which acts as a key protease responsible 
for the removal of the invariant chain from MHC class 
II antigens [53]. SLC11A1 encodes natural resistance-
associated macrophage protein 1, which acts as a host 
resistance to certain pathogens [54].  
 
Major Histocompatibility Complex Class II (MHC-II) 
DR β1 protein, encoded by HLA-DRB-1, plays a central 
role in the immune system by presenting peptides 
derived from extracellular proteins [55, 56] and 
participate  in the  activation  of   autophagosomes  [57].  
PDCD1LG2 codes for Programmed Cell Death 1 
Ligand 2, a protein involved in co-stimulatory signals 
essential for T-cell proliferation and IFN-γ production 
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[58]. IFNγ gene, which codes for the cytokine 
interferon-γ, is key player in antigen-specific immune 
responses [59]. Finally, interleukin 33, encoded by 
IL33, acts as a chemo-attractant for Th2 cells and 
functions as an ‘alarm’ that amplifies immune responses 
during tissue injury [60].  
 
Increased inflammatory response in the anterior horn of 
the spinal cord has been further documented by 
immunohistochemistry showing increased expression of 
IBA-1, the protein encoded by AIF1, CD68, and HLA-
DRB1 and HLA-DRB5 in reactive microglia. Reactive 
microglia has a round, amoeboid morphology and is 
also localized, as expected in the lateral and anterior 
pyramidal tracts. IL-10 and TNF-α are mainly localized 
in neurons of the spinal cord, and its expression is 
increased in remaining motor neurons of the spinal cord 
in ALS.  These findings indicate a parallelism between 
gene expression and protein expression regarding 
inflammatory responses of assessed molecules. On the 
other hand the different localization of microglial 
markers, and IL-10 and TNF-α in neurons points to a 
cross-talk between microglia and neurons in the anterior 
horn of the spinal cord in ALS.   
 
This is in contrast with other markers as glial fibrillary 
acidic protein and voltage dependent anion channel in 
which levels of mRNA differ from levels (or intensity) 
of protein expression. No modifications in the 
expression of GFAP mRNA are observed in the present 
study, but GFAP immunoreactivity is clearly increased 
in reactive astrocytes, as already reported in classical 
neuropathological studies. VDAC mRNA is not 
abnormally regulated in gene arrays; yet VDAC is 
decreased in motor neurons, but not in neurons of the 
Clarke’s column and neurons of the posterior horn, of 
the spinal cord in ALS. VDAC immunohistochemistry 
is in line with observations in human sALS showing 
deficiencies in mitochondria and energy metabolism 
[61, 62].  
 
Reduced expression of axolemal genes in anterior 
horn of the spinal cord 
 
The expression levels of NEFH, which codes for 
neurofilament heavy polypeptide protein [63], are 
preserved in ALS. However, DNAAF1, which encodes 
dynein (axonemal) assembly factor 1, and mRNAs 
encoding several dynein axonemal heavy chains (DHC) 
are down-regulated thus suggesting impairment of 
motor ATPases involved in the transport of various 
cellular cargoes by ‘walking’ along cytoskeletal 
microtubules towards the minus-end of the microtubule 
[64-66].  
Up-regulation of neurotransmission-related genes 
and synaptic cleft genes in frontal cortex  
 
Genes involved in glutamatergic and GABAergic 
transmission are up-regulated in the frontal cortex in 
ALS.  This applies to genes encoding the ionotropic 
glutamate receptor AMPA 1 (GRIA1), glutamate 
ionotropic receptor NMDA type subunit 2A (GRIN2A), 
the glutamate ionotropic receptor NMDA type subunit 
2B (GRIN2B), and glutamate metabotropic receptor 5 
(GRM5). Regarding the GABAergic system, GAD1, 
coding for glutamate decarboxylase 1, a rate-limiting 
enzyme that acts in the decarboxylation of glutamate 
essential for the conversion reaction of GABA from 
glutamate [67, 68], is up-regulated, as are GABRA1, 
GABRD, GABRB2, which code for different subunits of 
ionotropic GABA-A receptors. GABBR2, which codes 
for the metabotropic receptor component Gamma-
Aminobutyric Acid Type B Receptor Subunit 2 and 
forms heterodimers with GABBR1, thus resulting in the 
formation of the G-protein coupled receptor for GABA 
[69], is also up-regulated in ALS.  
 
In line with increased expression of neurotransmitter-
related genes, several genes encoding molecules linked 
with the synaptic cleft are also up-regulated in ALS. 
BSN codes for Bassoon, a pre-synaptic cytoskeletal 
matrix (PCM) protein acting as a scaffolding protein 
and essential for the regulation of neurotransmitter 
release in a subset of synapses [70, 71]. PCLO codes for 
Piccolo protein, a component of the PCM assembled in 
the active zone of neurotransmitter release [72, 73]. 
FRMPD4 codes for PSD-95-interacting regulator of 
spine morphogenesis protein which regulates dendritic 
spine morphogenesis and is required for the 
maintenance of excitatory synaptic transmission [74]. 
DDN and NRN1 code for dendrin protein and neuritin 1 
protein, respectively which are involved in the 
remodeling of the postsynaptic cytoskeleton and 
neuritic outgrowth [75-77].  
 
De-regulation of neurotransmitters and receptors is 
further supported by the demonstration of significant 
increase in the levels of GluR-1 and a tendency in those 
of GABAAB2 in the frontal cortex area 8 in ALS when 
compared with controls. It is worth stressing that only a 
few antibodies of the total assessed (eight) were suitable 
for western blotting.   
 
Myelin and oligodendrocyte genes in frontal cortex 
area 8    
 
Myelin transcription factor (encoded by MYRF) 
regulates oligodendrocyte differentiation and is required 
for central nervous system myelination [78-81]. The 
basic loop- helix protein OLIG2 mediates motor neuron 
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and oligodendrocyte differentiation [22, 82]. High 
mobility group protein SOX10 modulates myelin 
protein transcription [83, 84]. NKX2.2 homeodomain 
transcription factor is a key regulator of 
oligodendrocyte differentiation [85]. Transferrin 
encoded by TF participates in the early stages of 
myelination [86, 87]. Proteolipid protein 1 (encoded by 
PLP1) plays a role in the compaction, stabilization, and 
maintenance of myelin sheaths, as well as in 
oligodendrocyte development and axonal survival [88, 
89]. Myelin basic protein (encoded by MBP) is the 
second most abundant myelin-associated protein, 
constituting about 30% of total myelin protein [90]. 
Myelin-associated oligodendrocyte basic protein 
(encoded by MOBP) constitutes the third most abundant 
protein in CNS myelin and it acts by compacting and 
stabilizing myelin sheaths [91]. Myelin oligodendrocyte 
glycoprotein (encoded by MOG) is a cell surface marker 
of oligodendrocyte maturation [92]. Myelin associated 
glycoprotein (encoded by MAG) is a type I membrane 
protein and member of the immunoglobulin super-
family involved in the process of myelination and 
certain myelin-neuron cell-cell interactions [93]. Mal T-
cell differentiation protein (encoded by MAL) is 
involved in myelin biogenesis [94]. Finally, 2',3'-cyclic 
nucleotide 3' phosphodiesterase (encoded by CNP1) 
participates in early oligodendrocyte differentiation and 




Results of the present study validate gene expression of 
individual studies performed in a limited number of 
samples identifying a limited number of de-regulated 
genes in the anterior horn of the spinal cord [17, 20, 21, 
25]. Present results are more close to those carried out 
by using laser micro-dissection of anterior horn spinal 
motor neurons [27] thus reinforcing the consistence of 
observations in both studies. Whether some changes are 
related to the variable progression of the disease need 
further study with a larger number of cases of rapid or 
slow clinical course. In this line, altered mitochondria, 
protein degradation and axonal transport predominate in 
the 129Sv-SOD1(G93A) transgenic mouse with rapidly 
progressive motor neuron disease, whereas increased 
immune response is found in the C57-SOD1(G93A) 
transgenic mouse with more benign course [98].   
 
The most important aspect of the present study is the 
description of altered gene expression and identification 
of altered clusters of genes in the frontal cortex area 8 in 
sALS cases without apparent cognitive impairment. It is 
worth stressing that altered clusters differ in the spinal 
cord and frontal cortex in sALS at terminal stages thus 
providing valuable information of molecular ab-
normalities which can also be present within the 
spectrum of FTLD-TDP. Noteworthy, altered regulation 
of transcription related to synapses and neuro-
transmission covering neurotransmitter receptors, 
synaptic proteins and ion channels in the frontal cortex 
in the absence of overt clinical symptoms of cognitive 
impairment are particularly important to identify early 
molecular alterations in frontal cortex with the spectrum 
of ALS/FTLD-TDP.    
 




Post-mortem fresh-frozen lumbar spinal cord (SC) and 
frontal cortex (FC) (Brodmann area 8) tissue samples 
were from the Institute of Neuropathology HUB-ICO-
IDIBELL Biobank following the guidelines of Spanish 
legislation on this matter and the approval of the local 
ethics committee. The post-mortem interval between 
death and tissue processing was between 2 and 17 
hours. One hemisphere was immediately cut in coronal 
sections, 1-cm thick, and selected areas of the 
encephalon were rapidly dissected, frozen on metal 
plates over dry ice, placed in individual air-tight plastic 
bags, numbered with water-resistant ink and stored at -
80°C until use for biochemical studies. The other 
hemisphere was fixed by immersion in 4% buffered 
formalin for 3 weeks for morphologic studies. 
Transversal sections of the spinal cord were 
alternatively frozen at -80°C or fixed by immersion in 
4% buffered formalin. The whole series included 18 
sALS cases and 23 controls. The anterior horn of the 
spinal cord was examined in 14 sALS (mean age 57 
years; 6 men and 8 women) and the frontal cortex area 8 
in 15 sALS (mean age 54 years; 11 men and 4 women). 
Spinal cord and frontal cortex were available in 11 
cases. Lumbar anterior spinal cord was dissected on a 
dry-ice frozen plate under a binocular microscope at a 
magnification x4. TDP-43-immunoreactive small 
dystrophic neurites and/or TDP-43-positive granules 
and/or small cytoplasmic globules in cortical neurons in 
the contralateral frontal cortex area 8 were observed in 
11 of 18 cases, but only abundant in three cases (cases 
29, 30 and 31 in Table 3). Spongiosis in the upper 
cortical layers was found only in one case (case 28 in 
Table 3). Cases with frontotemporal dementia were not 
included in the present series. Patients with associated 
pathology including Alzheimer’s disease (excepting 
neurofibrillary tangle pathology stages I-II of Braak and 
Braak), Parkinson's disease, tauopathies, vascular 
diseases, neoplastic diseases affecting the nervous 
system, metabolic syndrome, hypoxia and prolonged 
axonal states such as those occurring in intensive care 
units were excluded. Cases with infectious, 
inflammatory and autoimmune diseases, either systemic 
or limited to the nervous system were not included.  



















































































































      RIN value 
Case Age Gender Diagnosis PM delay Initial symptoms SC FC 
1 49 F Control 07 h 00 min - - 7.2 
2 75 F Control 03 h 00 min - - 7.2 
3 55 M Control 05 h 40 min - - 7.7 
4 59 M Control 12 h 05 min - 6.4 - 
5 59 M Control 07 h 05 min - - 7.8 
6 43 M Control 05 h 55 min - 6.6 7.7 
7 53 M Control 07 h 25 min - - 5.3 
8 56 M Control 03 h 50 min - - 7.6 
9 47 M Control 04 h 55 min - 5.6 7.7 
10 64 F Control 11 h 20 min - 6.2 - 
11 46 M Control 15 h 00 min - 5.9 7.9 
12 56 M Control 07 h 10 min - 6.1 - 
13 71 F Control 08 h 30 min - 5.9 - 
14 64 F Control 05 h 00 min - 7.0 - 
15 79 F Control 06 h 25 min - 6.7 - 
16 75 M Control 07 h 30 min - 5.0 - 
17 55 M Control 09 h 45 min - 5.3 - 
18 52 M Control 03 h 00 min - - 8.3 
19 52 M Control 04 h 40 min - - 6.3 
20 76 M Control 06 h 30 min - 6.6 - 
21 60 F Control 11 h 30 min - - 7.5 
22 51 F Control 04 h 00 min - 6.3 7.9 
23 54 M Control 08 h 45 min - - 7.0 
24 56 M ALS 10 h 50 min NA 7.1 - 
25 70 M ALS 03 h 00 min Respiratory 7.3 7.0 
26 77 M ALS 04 h 30 min NA 7.4 - 
27 56 F ALS 03 h 45 min NA 8.2 7.7 
28 59 M ALS 03 h 15 min NA 7.5 7.7 
29 63 F ALS 13 h 50 min Bulbar 6.8 8.2 
30 59 F ALS 14 h 15 min NA 6.4 6.7 
31 54 M ALS 04 h 50 min Spinal - 7.8 
32 76 M ALS 12 h 40 min Spinal - 7.4 
33 64 M ALS 16 h 30 min NA 6.3 7.3 
34 57 F ALS 04 h 00 min Bulbar 6.2 8.6 
35 75 F ALS 04 h 05 min Bulbar 6.8 6.8 
36 79 F ALS 02 h 10 min NA 7.0 - 
37 57 F ALS 10 h 00 min Bulbar 6.5 7.1 
38 50 M ALS 10 h 10 min Spinal - 5.9 
39 59 F ALS 02 h 30 min Spinal - 7.5 
40 46 M ALS 07 h 00 min Spinal 7.0 8.0 
41 69 F ALS 17 h 00 min Spinal 6.4 6.3 
Abbreviations:  ALS:  amyotrophic  lateral  sclerosis;  F:  female; M: male;  PM:  post‐mortem  delay  (hours, 
minutes); SC: anterior horn of  the spinal cord  lumbar  level; FC:  frontal cortex area 8; RIN: RNA  integrity 
www.aging‐us.com  843  AGING 
Age-matched control cases had not suffered from 
neurologic or psychiatric diseases, and did not have 
abnormalities in the neuropathologic examination, 
excepting sporadic neurofibrillary tangle pathology 
stages I-II of Braak and Braak. No C9ORF72, SOD1, 
TARDBP and FUS mutations occurred in any case. 




RNA from frozen anterior horn of the lumbar spinal 
cord and frontal cortex area 8 was extracted following 
the instructions of the supplier (RNeasy Mini Kit, 
Qiagen® GmbH, Hilden, Germany). RNA integrity and 
28S/18S ratios were determined with the Agilent 
Bioanalyzer (Agilent Technologies Inc, Santa Clara, 
CA, USA) to assess RNA quality, and the RNA 
concentration was evaluated using a NanoDrop™ 
Spectrophotometer (Thermo Fisher Scientific). Selected 
samples were analyzed by microarray hybridization 
with GeneChip® Human Gene 2.0 ST Array and WT 
Labeling Kit and microarray 7000G platform from 
Affymetrix® (Santa Clara, CA, USA).  Microarray 
service was carried out at the High Technology Unit 
(UAT) at Vall d’Hebron Research Institute (VHIR), 































Microarray data and statistical analysis 
 
Microarray data quality control, normalization and 
filtering were performed using bioconductor packages 
in an R programming environment for genes [99] which 
enabled data preprocessing for differential gene 
expression analysis and enrichment analysis. Gene 
selection was based upon their values using a test for 
differential expression between two classes (Student’s t-
test). Genes differentially expressed showed an 
absolute fold change > 2.0 in combination with a p-




Complementary DNA (cDNA) preparation used High-
Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA, USA) following the 
protocol provided by the supplier. Parallel reactions for 
each RNA sample run in the absence of MultiScribe 
Reverse Transcriptase to assess the lack of 
contamination of genomic DNA. TaqMan RT-qPCR 
assays were performed in duplicate for each gene on 
cDNA samples in 384-well optical plates using an ABI 
Prism 7900 Sequence Detection system (Applied 
































anterior horn of  the  spinal  cord and  frontal  cortex area 8  in ALS  cases and  controls  including 
probes for normalization (AARS, GUS‐β, HPRT‐1 and XPNPEP‐1). 
Gene Gene symbol Reference 
2',3'-Cyclic Nucleotide 3' Phosphodiesterase CNP Hs00263981_m1 
Alanyl-TRNA Synthetase  AARS Hs00609836_m1 
Allograft Inflammatory Factor 1 AIF1 Hs00741549_g1 
Bassoon Presynaptic Cytomatrix Protein BSN Hs01109152_m1 
Cathepsin C CTSC Hs00175188_m1 
Cathepsin S CTSS Hs00356423_m1 
C-X-C Motif Chemokine Ligand 8 IL8 Hs00174103_m1 
Dendrin DDN Hs00391784_m1 
Dynein (Axonemal) Assembly Factor 1 DNAAF1 Hs00698399_m1 
Dynein Axonemal Heavy Chain 11 DNAH11 Hs00361951_m1 
Dynein Axonemal Heavy Chain 2 DNAH2 Hs00325838_m1 
Dynein Axonemal Heavy Chain 5 DNAH5 Hs00292485_m1 
Dynein Axonemal Heavy Chain 7 DNAH7 Hs00324265_m1 
Dynein Axonemal Heavy Chain 9 DNAH9 Hs00242096_m1 
Dynein Axonemal Intermediate Chain 1 DNAI1 Hs00201755_m1 

















































































































Gamma-Aminobutyric Acid Type A Receptor Alpha 1 
Subunit 
GABRA1 Hs00971228_m1 
Gamma-Aminobutyric Acid Type A Receptor Beta 2 
Subunit 
GABRB2 Hs00241451_m1 
Gamma-Aminobutyric Acid Type A Receptor Delta 
Subunit 
GABRD Hs00181309_m1 
Gamma-Aminobutyric Acid Type B Receptor Subunit 2 GABBR2 Hs01554996_m1 
Glial Fibrillary Acidic Protein GFAP Hs00909240_m1 
Glutamate Decarboxylase 1 GAD1 Hs01065893_m1 
Glutamate Ionotropic Receptor AMPA Type Subunit 1 GRIA1 Hs00181348_m1 
Glutamate Ionotropic Receptor NMDA Type Subunit 2A GRIN2A Hs00168219_m1 
Glutamate Ionotropic Receptor NMDA Type Subunit 2B GRIN2B Hs01002012_m1 
Glutamate Metabotropic Receptor 5 GRM5 Hs00168275_m1 
Hypoxanthine Phosphoribosyltransferase 1 HPRT1 Hs02800695_m1 
Integrin Subunit Beta 4 ITGB4 Hs00173995_m1 
Interferon, Gamma IFNG Hs00989291_m1 
Interleukin 1 Beta IL1B Hs01555410_m1 
Interleukin 10 IL10 Hs00961622_m1 
Interleukin 10 Receptor Subunit Alpha IL10RA Hs00155485_m1 
Interleukin 10 Receptor Subunit Beta IL10RB Hs00988697_m1 
Interleukin 33 IL33 Hs00369211_m1 
Interleukin 6 IL6 Hs00985639_m1 
Interleukin 6 Signal Transducer IL6ST Hs00174360_m1 
Macrophage Antigen CD68 CD68 Hs02836816_g1 
Major Histocompatibility Complex, Class II, DR Beta 1/4/5 HLA-DRB Hs04192463_mH 
Mal T-Cell Differentiation Protein MAL Hs00360838_m1 
Myelin Associated Glycoprotein MAG Hs01114387_m1 
Myelin Basic Protein MBP Hs00921945_m1 
Myelin Oligodendrocyte Glycoprotein MOG Hs01555268_m1 
Myelin Regulatory Factor MYRF Hs00973739_m1 
Myelin-Associated Oligodendrocyte Basic Protein MOBP Hs01094434_m1 
Neuritin 1 NRN1 Hs00213192_m1 
Neurofilament, Heavy Polypeptide NEFH Hs00606024_m1 
Neuropilin And Tolloid Like 1 NETO1 Hs00371151_m1 
NK2 Homeobox 2 NKX2-2 Hs00159616_m1 
Oligodendrocyte Lineage Transcription Factor 2 OLIG2 Hs00377820_m1 
Piccolo Presynaptic Cytomatrix Protein PCLO Hs00382694_m1 
Programmed Cell Death 1 Ligand 2 PDCD1LG2 Hs01057777_m1 
Prostaglandin-Endoperoxide Synthase 2 PTGS2 Hs00153133_m1 































For each 10μL TaqMan reaction, 4.5μL cDNA was 
mixed with 0.5μL 20x TaqMan Gene Expression 
Assays and 5μL of 2x TaqMan Universal PCR Master 
Mix (Applied Biosystems). Table 4 shows identification 
numbers and names of TaqMan probes. The mean value 
of one house-keeping gene, hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1), was used as 
internal control for normalization of spinal cord 
samples, whereas the mean values of the three house-
keeping genes, alanyl-transfer RNA synthase (AARS), 
glucuronidase Beta (GUS-β) and X-prolyl amino-
peptidase (aminopeptidase P) 1 (XPNPEP1) were used 
as internal controls for normalization of frontal cortex 
samples [100, 101]. The parameters of the reactions 
were 50°C for 2 min, 95°C for 10 min, and 40 cycles of 
95°C for 15 sec and 60°C for 1 min. Finally, capture of 
all TaqMan PCR data used the Sequence Detection 
Software (SDS version 2.2.2, Applied Biosystems). The 
double-delta cycle threshold (ΔΔCT) method was used 
to analyze the data; results with T-student test. The 
significance level was set at * p < 0.05, ** p < 0.01 and 
*** p < 0.001, and tendencies at # < 0.1. Pearson’s 
correlation method assessed a possible linear 
association between TDP-43 pathology in frontal cortex 
area 8 and gene deregulation in the same region; 

































De-waxed sections, 4μm thick, of the lumbar spinal cord 
from control and ALS cases were processed in parallel 
for immunohistochemistry. Endogenous peroxidases 
were blocked by incubation in 10% methanol-1% H2O2 
for 15 min followed by 3% normal horse serum. Then the 
sections were incubated at 4ºC overnight with one of the 
primary antibodies: rabbit polyclonal antibodies to IBA-1 
(019-19749, Wako Chemicals Gmbh, Neuss, GE) were 
used at a dilution of 1:1,000; VDAC (voltage dependent 
anion channel, ab15895, Abcam, Cambridge, UK) at 
1:100; HLA-DRB1 (GTX104919, GeneTex, Barcelona, 
Spain) at 1:100; HLA-DRB5 (NBP2, Novusbio, 
Littleton, Colorado, USA) at 1:100; IL-10 (AP52181PU, 
ACRIS, ProAlt, Madrid, Spain) at 1:100; and GFAP 
(glial fibrillary acidic protein, RP014-S, Diagnostic 
Biosystem, Palex Medica, Sant Cugat, Spain) at 1:400. 
Mouse monoclonal antibodies to CD68 (ab955, Abcam, 
Cambridge, UK) and TNF-α (ab1793, Abcam, 
Cambridge, UK), were used at dilutions of 1:200 and 
1:150, respectively. Antibodies to GluT: SLC1A2 
(ab1783, Millipore, Billerica, MA, USA) were used at a 
dilution of 1:100. Following incubation with the primary 
antibody, the sections were incubated with EnVision + 
system peroxidase (Dako, Agilent, Santa Clara, CA, 
 
Proteolipid Protein 1 PLP1 Hs00166914_m1 
PSD-95-Interacting Regulator Of Spine Morphogenesis FRMPD4 Hs01568794_m1 
Solute Carrier Family 1 (Glial High Affinity Glutamate 
Transporter), Member 2 (EAAT-2) 
SLC1A2 Hs01102423_m1 
Solute Carrier Family 11 Member 1 SLC11A1 Hs01105516_m1 
Solute Carrier Family 17 (Vesicular Glutamate 
Transporter), Member 7 (VGLUT-1) 
SLC17A7 Hs00220404_m1 
SRY (Sex Determining Region Y)-Box 10 SOX10 Hs00366918_m1 
Toll Like Receptor 2 TLR2 Hs00610101_m1 
Toll Like Receptor 3 TLR3 Hs01551078_m1 
Toll Like Receptor 4 TLR4 Hs01060206_m1 
Toll Like Receptor 7 TLR7  Hs00152971_m1 
Transferrin TF Hs01067777_m1 
Tumor Necrosis Factor Receptor Superfamily Member 1A TNFRSF1 Hs01042313_m1 
Tumor Necrosis Factor-Alpha TNFa Hs01113624_g1 
X-prolyl aminopepidase P1  XPNPEP1 Hs00958026_m1 
β-glucuronidase GUS-β Hs00939627_m1 
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USA) for 30 min at room temperature. The peroxidase 
reaction was visualized with diamino-benzidine and 
H2O2. Control of the immunostaining included omission 
of the primary antibody; no signal was obtained 
following incubation with only the secondary antibody. 
Sections were slightly stained with haematoxylin. 
 
Gel electrophoresis and western blotting 
 
Frozen samples of the somatosensory cortex were 
homogenized in RIPA lysis buffer composed of 50mM 
Tris/HCl buffer, pH 7.4 containing 2mM EDTA, 0.2% 
Nonidet P-40, 1mM PMSF, protease and phosphatase 
inhibitor cocktail (Roche Molecular Systems, USA). 
The homogenates were centrifuged for 20 min at 12,000 
rpm. Protein concentration was determined with the 
BCA method (Thermo Scientific). Equal amounts of 
protein (20μg) for each sample were loaded and 
separated by electrophoresis on 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
gels and transferred onto nitrocellulose membranes 
(Amersham, Freiburg, GE). Non-specific bindings were 
blocked by incubation in 3% albumin in PBS containing 
0.2% Tween for 1 h at room temperature. After 
washing, membranes were incubated overnight at 4°C 
with antibodies against glutamate receptor ionotropic, 
NMDA 2A (NMDAR2A, 130 kDa, rabbit, 1:200, 
Abcam, Cambridge, UK), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor 1 (AMPAR 
GluR-1, 100 kDa, rabbit, 1:200, Cell Signaling 
Technology, Danvers, MA, USA), glutamate decarbo-
xylase 1 (GAD1, 67 kDa, rabbit, 1:200, Cell Signaling 
Technology, Danvers, MA, USA) and gamma-
aminobutyric acid receptor subunit beta-2 (GABAAB2, 
59 kDa, mouse, 1:1000, Abcam, Cambridge, UK). 
Protein loading was monitored using an antibody 
against β-actin (42 kDa, 1:30,000, Sigma). Membranes 
were incubated for 1 h with appropriate HRP-
conjugated secondary antibodies (1:2,000, Dako); the 
immunoreaction was revealed with a chemilumines-
cence reagent (ECL, Amersham). Densitometric 
quantification was carried out with the ImageLab v4.5.2 
software (BioRad), using β-actin for normalization. 
Seven samples of FC area  8  per  group  were  analyzed.  
These antibodies were selected on the basis of a larger 
screening which included antibodies against proteins 
whose RNA levels were de-regulated as revealed by 
RT-qPCR. Only antibodies working for western blotting 
were eventually assessed.  The significance level was 
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